Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Debt Repayments (2021 - 2023)

InMed Pharmaceuticals (INM) has 3 years of Long-Term Debt Repayments data on record, last reported at $94400.0 in Q4 2023.

  • For Q4 2023, Long-Term Debt Repayments fell 12.76% year-over-year to $94400.0; the TTM value through Dec 2023 reached $410572.0, up 9.54%, while the annual FY2023 figure was $426575.0, 46.68% up from the prior year.
  • Long-Term Debt Repayments reached $94400.0 in Q4 2023 per INM's latest filing, down from $98709.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $109085.0 in Q2 2023 and bottomed at $17411.0 in Q3 2021.
  • Average Long-Term Debt Repayments over 3 years is $91051.0, with a median of $104206.5 recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: soared 479.54% in 2022, then decreased 12.76% in 2023.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $107712.0 in 2021, then grew by 0.46% to $108209.0 in 2022, then decreased by 12.76% to $94400.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $94400.0 in Q4 2023, $98709.0 in Q3 2023, and $109085.0 in Q2 2023.